Cargando…

Platelet-rich plasma (PRP): an adjuvant to hasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592)

BACKGROUND: Muscle injuries are one of the commonest injuries affecting athletes. It often leads to significant pain and disability causing loss of training and competition time. With current treatment, the duration to return-to-play ranges form six weeks to never, depending on injury severity. Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: A Hamid, Mohamad Shariff, Mohamed Ali, Mohamed Razif, Yusof, Ashril, George, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493370/
https://www.ncbi.nlm.nih.gov/pubmed/22866670
http://dx.doi.org/10.1186/1471-2474-13-138
_version_ 1782249253875220480
author A Hamid, Mohamad Shariff
Mohamed Ali, Mohamed Razif
Yusof, Ashril
George, John
author_facet A Hamid, Mohamad Shariff
Mohamed Ali, Mohamed Razif
Yusof, Ashril
George, John
author_sort A Hamid, Mohamad Shariff
collection PubMed
description BACKGROUND: Muscle injuries are one of the commonest injuries affecting athletes. It often leads to significant pain and disability causing loss of training and competition time. With current treatment, the duration to return-to-play ranges form six weeks to never, depending on injury severity. Recent researches have suggested that autologous platelet-rich plasma (PRP) injection into the injured site may hasten soft tissues healing. To-date, there has been no randomised clinical trials to evaluate the effects of PRP on muscle healing. The aim of this study is to examine the effects of autologous PRP on duration to return-to-play after muscle injury. METHODS AND DESIGN: A randomised, single blind controlled trial will be conducted. Twenty-eight patients aged 18 years and above with a recent grade-2 hamstring injury will be invited to take part. Participants will be randomised to receive either autologous PRP injection with rehabilitation programme, or rehabilitation programme only. Participants will be followed up at day three of study and then weekly for 16 weeks. At each follow up visit, participants will be assessed on readiness to return-to-play using a set of criteria. The primary end-point is when participants have fulfilled the return-to-play criteria or end of 16 weeks. The main outcome measure of this study is the duration to return-to-play after injury. CONCLUSION: This study protocol proposes a rigorous and potential significant evaluation of PRP use for grade-2 hamstring injury. If proven effective such findings could be of great benefit for patients with similar injuries. TRIAL REGISTRATION: Current Controlled Trials ISCRTN66528592
format Online
Article
Text
id pubmed-3493370
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34933702012-11-09 Platelet-rich plasma (PRP): an adjuvant to hasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592) A Hamid, Mohamad Shariff Mohamed Ali, Mohamed Razif Yusof, Ashril George, John BMC Musculoskelet Disord Study Protocol BACKGROUND: Muscle injuries are one of the commonest injuries affecting athletes. It often leads to significant pain and disability causing loss of training and competition time. With current treatment, the duration to return-to-play ranges form six weeks to never, depending on injury severity. Recent researches have suggested that autologous platelet-rich plasma (PRP) injection into the injured site may hasten soft tissues healing. To-date, there has been no randomised clinical trials to evaluate the effects of PRP on muscle healing. The aim of this study is to examine the effects of autologous PRP on duration to return-to-play after muscle injury. METHODS AND DESIGN: A randomised, single blind controlled trial will be conducted. Twenty-eight patients aged 18 years and above with a recent grade-2 hamstring injury will be invited to take part. Participants will be randomised to receive either autologous PRP injection with rehabilitation programme, or rehabilitation programme only. Participants will be followed up at day three of study and then weekly for 16 weeks. At each follow up visit, participants will be assessed on readiness to return-to-play using a set of criteria. The primary end-point is when participants have fulfilled the return-to-play criteria or end of 16 weeks. The main outcome measure of this study is the duration to return-to-play after injury. CONCLUSION: This study protocol proposes a rigorous and potential significant evaluation of PRP use for grade-2 hamstring injury. If proven effective such findings could be of great benefit for patients with similar injuries. TRIAL REGISTRATION: Current Controlled Trials ISCRTN66528592 BioMed Central 2012-08-06 /pmc/articles/PMC3493370/ /pubmed/22866670 http://dx.doi.org/10.1186/1471-2474-13-138 Text en Copyright ©2012 A Hamid et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
A Hamid, Mohamad Shariff
Mohamed Ali, Mohamed Razif
Yusof, Ashril
George, John
Platelet-rich plasma (PRP): an adjuvant to hasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592)
title Platelet-rich plasma (PRP): an adjuvant to hasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592)
title_full Platelet-rich plasma (PRP): an adjuvant to hasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592)
title_fullStr Platelet-rich plasma (PRP): an adjuvant to hasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592)
title_full_unstemmed Platelet-rich plasma (PRP): an adjuvant to hasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592)
title_short Platelet-rich plasma (PRP): an adjuvant to hasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592)
title_sort platelet-rich plasma (prp): an adjuvant to hasten hamstring muscle recovery. a randomized controlled trial protocol (iscrtn66528592)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493370/
https://www.ncbi.nlm.nih.gov/pubmed/22866670
http://dx.doi.org/10.1186/1471-2474-13-138
work_keys_str_mv AT ahamidmohamadshariff plateletrichplasmaprpanadjuvanttohastenhamstringmusclerecoveryarandomizedcontrolledtrialprotocoliscrtn66528592
AT mohamedalimohamedrazif plateletrichplasmaprpanadjuvanttohastenhamstringmusclerecoveryarandomizedcontrolledtrialprotocoliscrtn66528592
AT yusofashril plateletrichplasmaprpanadjuvanttohastenhamstringmusclerecoveryarandomizedcontrolledtrialprotocoliscrtn66528592
AT georgejohn plateletrichplasmaprpanadjuvanttohastenhamstringmusclerecoveryarandomizedcontrolledtrialprotocoliscrtn66528592